Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 3/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | CASK | O14936 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.38 |
| ▸ | CDK14 | O94921 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | MAK | P20794 | 1/20 | 0.38 |
| ▸ | CDK11B | P21127 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83595 | 0.93 | PKM (0.40) | CDK2CDK1CCNB1CCNB2CCNE1 | |
| SCHEMBL83622 | 0.86 | CHRM4 (0.42) | CLK4DYRK1ASLKPKMROCK2 | |
| SCHEMBL5014883 | 0.80 | CSF1R (0.36) | CDK2CDK1CCNB1CCNB2CCNE1 | |
| SCHEMBL82345 | 0.79 | CSF1R (0.39) | CDK2CDK1CCNB1CCNB2CCNE1 | |
| SCHEMBL79935 | 0.78 | CSF1R (0.39) | CDK2CDK1CCNB1CCNB2CCNE1 | |
| SCHEMBL80255 | 0.78 | ROCK2 (0.43) | ROCK2ROCK1 | |
| SCHEMBL5030203 | 0.77 | PKM (0.38) | PKMHPGDS | |
| SCHEMBL81783 | 0.76 | CSF1R (0.40) | CDK2CDK1CCNB1CDK5CLK4 | |
| SCHEMBL83293 | 0.76 | GSK3A (0.38) | CDK2CCNE1GSK3AGSK3BROCK2 | |
| SCHEMBL5028849 | 0.76 | FLT3 (0.37) | CDK2CDK1CCNB1CCNB2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | CDK2 109/4885CCNA2 1019/4885CCNA1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.